REGN10933+REGN10987 combination therapy

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

COVID-19

Phase 1

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

CompletedNCT04426695

Regeneron PharmaceuticalsCOVID-19

Start: 2020-06-10End: 2021-10-22Updated: 2023-01-27

Phase 2

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

CompletedNCT04666441

Regeneron PharmaceuticalsCOVID-19

Start: 2020-12-15End: 2021-09-21Updated: 2022-04-08

Unknown Phase

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

Regeneron PharmaceuticalsCOVID-19

Updated: 2023-10-03

Related Papers

Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial

Open Forum Infectious Diseases2023-04-192 citations

1079. Casirivimab and Imdevimab (CAS + IMD) Antibody Combination for the Treatment of Immunocomprised Hospitalized Patients with COVID-19

Open Forum Infectious Diseases2022-12-01

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection

JAMA Network Open2022-08-1517 citations

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

The Journal of Infectious Diseases2022-07-2746 citations

Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response.

2022-06-0136 citations

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2022-02-01340 citations

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

New England Journal of Medicine2021-09-29620 citations